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INTRODUCTION: To examine the association between phosphodiesterase-5 (PDE-5) inhibitor use and incidence of colorectal

cancer among patients with erectile dysfunction treated in the Veterans Affairs (VA) Healthcare System.
METHODS:

A retrospective cohort study using the Veterans Affairs Informatics and Computing Infrastructure was
conducted, with data spanning January 2001–December 2016. Patients were followed up from index
until (i) the first diagnosis of colorectal cancer, (ii) death, or (iii) the end of study period. Statistical
analyses evaluated demographics and baseline characteristics between cohorts (PDE-5 exposed or not)
and the effect of additional dosages of each specific PDE-5 inhibitor using adjusted multivariate Cox
proportional hazards models.

RESULTS:

A total of 221,538 patients met the study inclusion criteria, 192,691 patients in the PDE-5 cohort and
29,227 patients in the never use PDE-5 cohort. The multivariate Cox proportional hazards model results
revealed that the those who had any exposure to a PDE-5 inhibitor have an 18% lower hazard of
colorectal cancer (adjusted hazard ratio [HR] 5 0.816, 95% confidence interval [CI] 5 0.754–0.882).
For each additional 100-mg dosage of sildenafil and 10-mg dosage of tadalafil, the hazard of colorectal
cancer is reduced by 2.4% (adjusted HR 5 0.976, 95% CI 5 0.973–0.979) and 1.7% (adjusted HR 5
0.983, 95% CI 5 0.972–0.996), respectively.

DISCUSSION:

PDE-5 inhibitor usage in patients with erectile dysfunction is associated with a lower hazard of
colorectal cancer compared with patients not exposed to PDE-5 inhibitors.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A281
Clinical and Translational Gastroenterology 2020;11:e00173. https://doi.org/10.14309/ctg.0000000000000173

INTRODUCTION
Colorectal cancer is one of the most common and deadly cancers
(1). Research suggests that phosphodiesterases (PDEs) are involved
in the development and progression of colorectal cancer (2,3). One
type of PDE isozyme is the PDE-5, which is speciﬁc to cyclic
guanosine monophosphate. Currently, PDE-5 inhibitors are approved by the US Food and Drug Administration to treat erectile
dysfunction (t) (4). However, PDE-5 inhibitors may be a viable
chemopreventive agent. Evidence suggests that targeting cyclic
guanosine monophosphate with PDE-5 inhibitors can reduce the
incidence of intestinal cancer via altering epithelial homeostasis (5).
Furthermore, recent preclinical studies including in vivo, in vitro,
and mouse studies suggest that PDE-5 inhibitor use may reduce the
risk of colorectal cancer (4,6–11).
Given the preclinical evidence, the purpose of this study is to
evaluate the association between PDE-5 inhibitor use and incident colorectal cancer diagnosis in a large national cohort.

METHODS
Data

This retrospective cohort study was conducted using data from the
Department of Veterans Aﬀairs. The Veterans Aﬀairs Informatics
and Computing Infrastructure was used to obtain individual-level
information on demographics, administrative claims, and pharmacy dispensation. The completeness, utility, accuracy, validity,
and access methods are described on the Veterans Aﬀairs (VA)
website, http://www.virec.research.va.gov. The study was conducted in compliance with the Department of Veterans Aﬀairs
requirements and received the Institutional Review Board and
Research and Development approval. The study used the inpatient
and outpatient data (coded with International Classiﬁcation of
Diseases [ICD] revision 9-CM, revision 10-CM, Current Procedure
Terminology) and pharmacy, laboratory, and vital sign data, which
include height, weight, and blood pressure, over the time period
January 2000–December 2018.
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Cohort selection

The cohort for this study includes all male veterans aged 18 years
and older with a diagnosis of ED. ICD revision 9 and 10 codes
including 302.72, 607.84, and N52.9x were used to code ED between January 2001 and December 31, 2016. The study index date
for patients was deﬁned as the ﬁrst diagnosis of ED. The study
period, for each patient, was deﬁned as the time between index and
study endpoint. The baseline period was deﬁned as 1 year before
study index.
We used several exclusionary criteria. Patients were included if they
had at least 1 year between their VA enrollment date and study index
date. To account for latency bias, patients were excluded if they had
a diagnosis of colorectal cancer or died up until 1 year after index
(12,13). Patients were excluded if they did not have any values of
estimated glomerular ﬁltration rate (eGFR), systolic, diastolic blood
pressure, body mass index (BMI), or serum cholesterol during the
baseline period to ensure proper medical surveillance. Furthermore,
patients who had a PDE-5 inhibitor prescription during baseline
were excluded. Patients with prescriptions for nitroglycerin were
excluded from the study because PDE-5 inhibitors are contraindicated for patients on nitroglycerin. To ensure whether patients
had the opportunity to be diagnosed with colorectal cancer, all
patients were required to have at least 1 colonoscopy during the
study period. Colonoscopies were extracted from the outpatient
claims using Current Procedure Terminology codes: 45378-45398.
Patients with pulmonary arterial hypertension were excluded using
the ICD-9/10 diagnosis codes (416.0, 416.8, 416.9, I27.2x, I27.81,
I27.89, and I27.9) and any patient with a PDE-5 inhibitor prescription for greater than 1 pill per day. Pills per day were calculated
using the quantity supplied divided by the days supplied. Patients
were followed up from index until
1. the ﬁrst diagnosis of colorectal cancer
2. death
3. the end of study period December 31, 2018.
Outcome

The outcome for this study was the development of colorectal
cancer, deﬁned as the ﬁrst diagnosis of the following ICD-9 and
10 codes: 153.x, 154.0, 154.1, C18.3, C18.4, C18.5, C18.6, C18.7,
C18.8, C18.9, C19, and C20 (12).

and serum cholesterol were extracted using logical observation
identiﬁers names and codes (see Appendix, Supplementary Digital
Content 1, http://links.lww.com/CTG/A281). Diagnoses of the
family history of gastrointestinal malignant neoplasm, diabetes,
tobacco usage were coded based on the ICD-9 and ICD-10 diagnoses codes (see Appendix, Supplementary Digital Content 1,
http://links.lww.com/CTG/A281).
Statistical analysis

The statistical analysis occurred in 2 steps. First, we compared the
baseline characteristics between those exposed to PDE5 inhibitors
and the never exposed patients. Second, we displayed the
Kaplan–Meier survival curves for the PDE-5 exposed and unexposed cohorts to display the unadjusted survival curves. We used
the multivariate Cox proportional hazards models to estimate the
hazard of developing colorectal cancer. Our initial model compares
the hazard of those exposed to any PDE-5 inhibitor with that of
those never exposed. Next, we estimated the eﬀect of additional
dosages of each speciﬁc PDE-5 inhibitor; however, avanaﬁl was
excluded from drug-speciﬁc models because of low sample counts.
A subanalysis was conducted on patients who had monotherapy
(i.e., exposed to only 1 PDE-5 inhibitor) compared with those who
were never exposed to sildenaﬁl or vardenaﬁl (due to sample sizes).
In addition to estimating the hazard ratios per additional dosages,
we also estimated the hazard ratios for the total number of PDE-5
prescriptions. Prescription counts were categorized into 5 groups
(1–4, 5–10, 11–15, 16–20, and 211).

RESULTS
In this study, we found 1.7 million male veterans with a diagnosis
for ED over the years 2001–2016. We excluded 406,385 patients
who had a PDE-5 inhibitor prescribed before study index. In total,
295,359 patients were excluded because they did not have at least 1
year between VA enrollment and study index; 2,081 patients who
had colorectal cancer up until 1 year after index were excluded;
13,392 patients were excluded because they died within 1 year after
index; 55,549 patients were excluded because they were missing
baseline laboratory test results; 155,668 patients with a prescription
for nitroglycerine were removed from the study; 573,987 patients
were excluded because they did not have a colonoscopy during the
study period; and 8,353 patients were excluded for pulmonary

Study variables

The primary predictor of interest is the use of PDE-5 inhibitors.
PDE-5 inhibitors comprised sildenaﬁl, tadalaﬁl, vardenaﬁl, and
avanaﬁl. We quantiﬁed the exposure to PDE-5 inhibitors in 2 ways.
First, patients who had at least 1 prescription for a PDE-5 inhibitor
were classiﬁed as PDE-5 inhibitor users and those without a prescription for a PDE-5 were classiﬁed as never users. Second, we
used the cumulative milligrams (mg) prescribed for each PDE-5
inhibitor. Dosages were extracted from the drug name and summed over the study period.
In addition to PDE-5 use, we also included covariates to account
for baseline demographic and health diﬀerences. Demographic
factors included age, race, and index year. Baseline health conditions included the Charlson comorbidity index, diabetes, tobacco
usage, BMI, systolic and diastolic blood pressure, eGFR (chronic
kidney disease-epi formula), total serum cholesterol, and family
history of gastrointestinal malignant neoplasm and inﬂammatory
bowel disease (IBD). Baseline laboratory values including eGFR
Clinical and Translational Gastroenterology

Figure 1. Study attrition. BMI, body mass index; ED, erectile dysfunction;
eGFR, estimated glomerular filtration rate; PDE, phosphodiesterase; VA,
Veterans Affairs.
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PDE-5 inhibitor use
Variable
Age

Never (N 5 29,227)

Yes (N 5 192,691)

P value

Std diff

60.51 (9.567)

57.13 (8.524)

,0.001

0.3739

,0.001

0.2886

Race
Asian

115 (0.393%)

Black

4,802 (16.402%)

Latino/Hispanic

916 (0.476%)
54,332 (28.26%)

98 (0.335%)

Other/unknown
White
Charlson comorbidity index

733 (0.381%)

2,234 (7.631%)

11,171 (5.81%)

22,028 (75.24%)

125,109 (65.072%)

1.17 (1.564)

0.75 (1.244)

,0.001

0.2930

,0.001

0.0482

,0.001

0.2455

,0.001

0.1125

BMI
Normal

4,370 (14.926%)

29,219 (15.198%)

Obese

13,856 (47.327%)

86,250 (44.861%)

Overweight

10,898 (37.224%)

75,778 (39.414%)

Underweight

153 (0.523%)

eGFR

78.89 (19.46)

1,014 (0.527%)
83.48 (17.979)

Total serum cholesterol (mg/dL)

181.91 (40.724)

Systolic blood pressure

133.29 (17.282)

132.2 (16.074)

,0.001

0.0652

Diastolic blood pressure

77.15 (10.971)

78.71 (10.408)

,0.001

0.1463

Family history of malignant GI neoplasm

186.46 (40.25)

245 (0.837%)

1,793 (0.933%)

0.117

0.0109

Diabetes

7,976 (27.243%)

39,360 (20.472%)

,0.001

0.1577

Smoking

4,807 (16.419%)

36,606 (19.04%)

,0.001

0.0682

290 (0.991%)

1,544 (0.803%)

0.001

0.0212

IBD
Statin use

10,618 (36.267%)

122,965 (63.957%)

,0.001

0.5766

NSAID use

20,311 (69.5%)

146,573 (76.1%)

,0.001

0.1487

0.132

0.0091

,0.001

0.2163

Index year

2,006.88 (4.282)

2,006.84 (3.913)

Days in study

3,502.84 (1,560.903)

3,828.63 (1,450.143)

Format: categorical variables N (%); continuous variables mean (SD).
BMI, body mass index; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; IBD, inflammatory bowel disease; NSAID, nonsteroidal anti-inflammatory drug;
PDE, phosphodiesterase.

arterial hypertension. After all exclusionary criteria, 221,538
patients remained in the study cohort (Figure 1).
Table 1 displays the demographic and baseline clinical characteristics for patients who never used a PDE-5 inhibitor (n 5 29,227)
and those who had at least 1 PDE-5 inhibitor prescription
(n 5 192,691). On average, those who never used a PDE-5 inhibitor
are older (60.51 vs 57.13 years, respectively), have a higher Charlson

comorbidity index (1.17 vs 0.75, respectively), have a lower eGFR
(78.89 vs 83.48), have lower total serum cholesterol (181.91 vs
186.46), and have a higher prevalence of diabetes (27.24% vs 20.47%).
Patients who took a PDE-5 inhibitor have a higher prevalence of
statin usage (63.95% vs 36.27%) and are more likely to be smokers
(19.04% vs 16.42%). The breakdown of PDE-5 use by drug is shown
in Table 2. Of the PDE-5 inhibitor users, 86% has at least 1

Table 2. PDE-5 inhibitor usage
PDE-5 inhibitor
Sildenafil
Tadalafil
Vardenafil
Avanafil

N (% all PDE-5)

Monotherapy N (% within drug)

Average cumulative mg dose (SD)

166,208 (86.449%)

50,758 (30.50%)

1,884 (2,514.19)

7,896 (4.107%)
140,067 (72.853%)
117 (0.061%)

202 (2.60%)
25,514 (18.20%)
1 (0.95%)

135.34 (227.69)
253.73 (306.12)
433.33 (517.28)

PDE, phosphodiesterase.
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Table 3. Multivariate Cox proportional hazards model estimating
the hazard of developing colorectal cancer
Variable

HR (95% CI)

PDE-5 inhibitor use (referent 5 never used)
Yes

0.828 (0.766–0.895)

Age

1.051 (1.047–1.055)

Race (referent 5 White)
Asian

1.188 (0.765–1.845)

Black

1.283 (1.196–1.376)

Latino/Hispanic

0.942 (0.567–1.565)

Other/unknown

0.831 (0.729–0.947)

Charlson comorbidity index

1.081 (1.056–1.106)

BMI (referent 5 underweight)

Figure 2. Kaplan–Meier survival curves. PDE, phosphodiesterase.

prescription for sildenaﬁl, 72% had a prescription for vardenaﬁl, 4%
for tadalaﬁl, and 0.9% for avanaﬁl. Among those with a sildenaﬁl
prescription, 30% had no other PDE-5 inhibitors. Among those with
a vardenaﬁl prescription, 18% had no other PDE-5 inhibitors. Among
those with tadalaﬁl exposure, 2.6% were exposed only to tadalaﬁl.
Among those exposed to avanaﬁl, only 1 patient was exposed only to
avanaﬁl. Figure 2 presents the unadjusted Kaplan–Meier survival
curves for those exposed and unexposed to a PDE-5 inhibitor. The
Kaplan–Meier curves showed a lower risk of colorectal cancer
throughout the study time. In Table 3, we present the results of the
Cox proportional hazard model, examining the association between
any PDE-5 inhibitor use and colorectal cancer. Those who had any
exposure to a PDE-5 inhibitor have an 18% lower hazard of colorectal
cancer (hazard ratio [HR] 5 0.816, 95% conﬁdence interval [CI] 5
0.754–0.882). Black patients had a higher hazard of colorectal cancer
compared with white patients (HR 5 1.168, 95% CI 5 1.089–1.252).
Other risk factors for colorectal cancer included age (HR 5 1.056,
95% CI 5 1.052–1.060), Charlson comorbidity (HR 5 1.067, 95% CI
5 1.042–1.093), total serum cholesterol (HR 5 1.005, 95% CI 5
1.003–1.007), diastolic blood pressure (HR 5 1.002, 95% CI 5
1.001–1.003), diabetes (HR 5 1.196, 95% CI 5 1.105–1.295),
smoking (HR 5 1.164, 95% CI 5 1.075–1.259), and IBD (HR 5
1.411, 95% CI 5 1.061–1.876). Statins, consistent with Poynter et al.
(14), are associated with a decrease in the hazard of colorectal cancer
(HR 5 0.613, 95% CI 5 0.576–0.652).
The results from the association between drug dosage and colorectal cancer are shown in Table 4. For each additional 100-mg
dosage of sildenaﬁl, the hazard of colorectal cancer is reduced by
2.4% (HR 5 0.976, 95% CI 5 0.973–0.979). For each additional 10mg dose of tadalaﬁl, the hazard of colorectal cancer is reduced by
1.7% (HR 5 0.983, 95% CI 5 0.972–0.996). We ﬁnd no statistically
signiﬁcant association for each additional 10-mg vardenaﬁl dose
(HR 5 1.000, 95% CI 5 0.999–1.002). Other results are similar to
those of the cox proportional hazards model examining the association between any PDE-5 inhibitor use and colorectal cancer.
Table 5 displays the subanalysis conducted on those with no PDE-5
inhibitor exposure and those with sildenaﬁl-only treatment, and
secondarily those with no PDE-5 inhibitor exposure and
vardenaﬁl-only treatment. We ﬁnd that each additional 100 mg of
sildenaﬁl, the hazard of colorectal cancer is reduced by 1% (HR 5
0.99, 95% CI 5 0.984–0.995). For each additional 10 mg of
Clinical and Translational Gastroenterology

Normal

1.24 (0.795–1.934)

Obese

1.277 (0.821–1.987)

Overweight

1.151 (0.74–1.789)

eGFR

1.001 (1–1.003)

Total serum cholesterol (mg/dL)

1.006 (1.003–1.008)

Systolic blood pressure

0.997 (0.993–1)

Diastolic blood pressure

1.002 (1.001–1.003)

Family history of malignant GI neoplasm

1.091 (0.802–1.484)

Diabetes
Smoking
IBD

1.23 (1.136–1.331)
1.211 (1.119–1.31)
1.32 (0.993–1.755)

Statins

0.632 (0.594–0.673)

Index year

0.938 (0.929–0.947)

NSAID use

0.449 (0.421–0.479)

BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular
filtration rate; GI, gastrointestinal; HR, hazard ratio; IBD, inflammatory bowel
disease; NSAID, nonsteroidal anti-inflammatory drug; PDE,
phosphodiesterase.

vardenaﬁl, there is an associated 0.7% higher hazard of colorectal
cancer (HR 5 1.007, 95% CI 5 1.002–1.011). Table 6 displays the
results of the Cox model estimating PDE-5 exposure by prescription counts. We found that patients with less than or equal to
10 prescriptions are not statistically signiﬁcantly diﬀerent in the
risk of colorectal cancer compared with the unexposed (1–4 HR 5
1.024, 95% CI 5 0.936–1.119; 5–10 HR 5 0.969, 95% CI 5
0.877–1.071). Patients with greater than 10 prescriptions for
a PDE-5 have a statistically signiﬁcantly lower risk of colorectal
cancer (11–15 HR 5 0.878, 95% CI 5 0.774–0.995; 16–20 HR 5
0.841, 95% CI 5 0.73–0.968; 211 HR 5 0.536, 95% CI 5
0.486–0.59). Furthermore, the estimates suggest that the risk of
colorectal cancer decreases for additional prescriptions of a PDE-5,
ultimately resulting in a 46% reduction in risk for those with 21 or
more prescriptions (211 HR 5 0.536, 95% CI 5 0.486–0.59).

DISCUSSION
In this study, among patients receiving care in the VA system
with ED, we found that those who had any exposure to a PDE-5
VOLUME 11 | JUNE 2020 www.clintranslgastro.com

Table 4. Multivariate Cox proportional hazards model estimating
the hazard of colorectal cancer by dose

Table 5. Multivariate Cox proportional hazards model estimating
the hazard of colorectal cancer for those on monotherapy

Variable

Variable

Sildenafil per additional 100 mg

HR (95% CI)
0.977 (0.974–0.979)

Tadalafil per additional 10 mg

0.985 (0.973–0.997)

Vardenafil per additional 10 mg

1.001 (0.999–1.002)

Age

1.044 (1.04–1.048)

Race (referent 5 White)

Sildenafil monotherapy
per additional 100 mg

1.245 (0.802–1.934)

Black

1.438 (1.341–1.543)

Age

Latino/Hispanic

1.026 (0.618–1.705)

Race (referent 5 White)

Other/unknown

0.839 (0.736–0.956)
1.071 (1.046–1.096)

BMI (referent 5 underweight)

HR (95% CI)

0.991 (0.986–0.997)
1.007 (1.003–1.011)

Vardenafil
monotherapy per
additional 10 mg

Asian

Charlson comorbidity index

HR (95% CI)

PDE-5 inhibitor use
(referent 5 never used)

1.047 (1.041–1.053)

1.041 (1.034–1.048)

Asian

1.55 (0.855–2.808)

1.006 (0.417–2.424)

Black

1.415 (1.265–1.583)

1.416 (1.249–1.606)

Latino/Hispanic

1.064 (0.506–2.237)

1.762 (0.878–3.536)

Normal

1.269 (0.814–1.979)

Other/unknown

0.858 (0.718–1.026)

0.856 (0.701–1.046)

Obese

1.279 (0.822–1.99)

Charlson comorbidity
index

1.089 (1.055–1.124)

1.062 (1.024–1.101)

Overweight

1.18 (0.758–1.835)

eGFR

1.002 (1–1.003)

Total serum cholesterol (mg/dL)

1.005 (1.003–1.007)

Systolic blood pressure

0.997 (0.994–1.001)

Diastolic blood pressure

1.002 (1.001–1.002)

Family history of malignant
GI neoplasm

1.088 (0.8–1.48)

Diabetes

1.197 (1.106–1.295)

Smoking

1.205 (1.114–1.304)

IBD

1.313 (0.987–1.746)

Statins

0.688 (0.647–0.732)

Index year

0.928 (0.919–0.938)

NSAID use

0.468 (0.439–0.499)

BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular
filtration rate; GI, gastrointestinal; HR, hazard ratio; IBD, inflammatory bowel
disease; NSAID, nonsteroidal anti-inflammatory drug.

inhibitor had a lower hazard of colorectal cancer. Furthermore,
we estimated the eﬀect of additional dosages of each speciﬁc
PDE-5 inhibitor (excluding avanaﬁl). We found for each additional 100-mg dosage of sildenaﬁl and each additional 10-mg
dose of tadalaﬁl, the hazard of colorectal cancer is reduced. In
the subanalysis, patients who had monotherapy with sildenaﬁl
only had a decreased hazard of colorectal cancer for each additional 100 mg of treatment. However, for each additional 10
mg of vardenaﬁl, there is a higher hazard of colorectal cancer for
those on vardenaﬁl only.
More in vivo studies have demonstrated the eﬀectiveness of
PDE-5 inhibitors eﬀect on the colon compared with in vitro
studies. Some in vivo studies showed that the sildenaﬁl suppressed the polyp multiplicity in the colon, even by 50% by
administering varying dosages of the inhibitor (6,7,10).
Growth inhibition of colon tumor cells occurred with the use of
PDE-5 inhibitors in vitro (and in vivo) while enhancing anticancer and other drugs (8,11). Mei et al. (4) demonstrated the
American College of Gastroenterology

BMI (referent 5
underweight)
Normal

1.146 (0.611–2.151)

1.26 (0.595–2.672)

Obese

1.184 (0.633–2.214)

1.314 (0.622–2.773)

Overweight

1.082 (0.579–2.023)

1.204 (0.571–2.54)

eGFR

1.002 (1–1.005)

1.002 (0.999–1.004)

Total serum cholesterol
(mg/dL)

1.003 (1–1.006)

1.004 (1.001–1.008)

Systolic blood pressure

1.001 (0.996–1.007)

1.001 (0.995–1.007)

Diastolic blood
pressure

1.002 (1.001–1.003)

1.002 (1.001–1.003)

Family history of
malignant GI neoplasm

1.006 (0.615–1.645)

1.089 (0.655–1.811)

Diabetes

1.187 (1.057–1.331)

1.142 (1.006–1.296)

Smoking

1.335 (1.185–1.503)

1.246 (1.093–1.421)

IBD

0.822 (0.502–1.345)

1.027 (0.617–1.708)

Statins

0.756 (0.691–0.828)

0.831 (0.75–0.922)

Index year

0.892 (0.881–0.904)

0.927 (0.912–0.943)

NSAID use

0.446 (0.406–0.49)

0.451 (0.407–0.5)

BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular
filtration rate; GI, gastrointestinal; HR, hazard ratio; IBD, inflammatory bowel
disease; NSAID, nonsteroidal anti-inflammatory drug; PDE,
phosphodiesterase.

eﬀect of sildenaﬁl on proliferation and apoptosis in vitro and in
vivo by implanting nude mice with SW480 or HCT116 human
cancer cells by administering sildenaﬁl orally. Similar results
were shown in vitro and in vivo with sildenaﬁl and tadalaﬁl
inhibiting tumor growth in immune-competent mice by
50%–70% (9).
Although there is a lack of observational studies evaluating
the association of the use of PDE-5 inhibitors and colorectal
cancer, some results from our study is consistent with other
Clinical and Translational Gastroenterology
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Table 6. Multivariate Cox proportional hazards model estimating
the hazard of colorectal by the number of refills
Variable

HR (95% CI)

PDE-5 exposure refill count
(referent 5 never used)
1–4

1.024 (0.936–1.119)

5–10

0.969 (0.877–1.071)

11–15

0.878 (0.774–0.995)

16–20

0.841 (0.73–0.968)

211

0.536 (0.486–0.59)

Age

1.046 (1.041–1.05)

Race (referent 5 White)
Asian

1.228 (0.791–1.907)

Black

1.397 (1.302–1.5)

Latino/Hispanic

0.989 (0.595–1.643)

Other/unknown

0.84 (0.737–0.957)

Charlson comorbidity index

1.073 (1.048–1.099)

BMI (referent 5 underweight)
Normal

1.251 (0.802–1.951)

Obese

1.263 (0.812–1.965)

Overweight

1.158 (0.745–1.802)

eGFR

1.001 (1–1.003)

Total serum cholesterol (mg/dL)

1.005 (1.003–1.007)

Systolic blood pressure

0.997 (0.994–1.001)

Diastolic blood pressure

1.002 (1.001–1.002)

Family history of malignant
GI neoplasm

1.09 (0.801–1.483)

Diabetes

1.21 (1.118–1.31)

Smoking

1.209 (1.117–1.308)

IBD

1.312 (0.987–1.745)

Statins

0.676 (0.635–0.72)

Index year

0.931 (0.922–0.941)

NSAID use

0.464 (0.436–0.495)

BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular
filtration rate; GI, gastrointestinal; HR, hazard ratio; IBD, inflammatory bowel
disease; NSAID, nonsteroidal anti-inflammatory drug; PDE,
phosphodiesterase.

studies. A UK-matched cohort study found a decreased risk for
colorectal cancer for those who were PDE-5 inhibitor users
(HR 5 0.91, 95% CI 5 0.85–0.98, P 5 0.01); however, they did
not limit their analyses to men with ED (15). In a Swedish study
of men diagnosed with benign colorectal neoplasm had a reduced risk of colorectal cancer (HR 5 0.65, 95% CI 5 0.49–0.85)
while using PDE-5 and an increased cumulative dosage of
PDE-5 (16). PDE-5 is eﬀective enough to selectively stimulate
apoptosis of colon tumor cells while having minimal eﬀects on
normal colon cells (17,18).
Some demographic and risk factors that we adjusted for in
our models are included in other literature concerning colorectal cancer. Diﬀerences in colorectal cancer are seen in
Clinical and Translational Gastroenterology

racial disparities, as blacks are associated with having a higher
incidence (19,20). Clinical studies of IBD report that patients
have a higher risk of colorectal cancer as well (7,21). Statin users
had a decreased risk of colorectal cancer compared with nonstatin users (13). Patients with diabetes, consistent with
Overbeek et al. (22), have an increased risk of developing colorectal cancer; however, the study did not account for smoking
status nor BMI in estimating models as we did. Unlike Mamtani
et al., we found an increased total serum cholesterol to be associated with an increased hazard of colorectal cancer similar to
another study (13,23). A meta-analysis demonstrated that
cigarette smoking is associated with an increased incidence and
mortality of colorectal cancer among a sample of 106 studies (24).
To our knowledge, this study is the ﬁrst population-based
study to examine the function of PDE-5 inhibitors along with
the risk of colorectal cancer among patients with ED. Our study
is unique because it (i) evaluated a national cohort of patients
with ED, (ii) evaluated patients who were prescribed PDE-5
inhibitors (sildenaﬁl, tadalaﬁl, vardenaﬁl, and avanaﬁl), and (iii)
evaluated PDE-5 usage 2 ways (binary and dosage). However,
like many observational studies, there are some factors that may
have inﬂuenced the outcomes which were not accounted for
within this study. First, the population is US male veterans with
ED; therefore, our ﬁndings may not be generalizable to other
patients. We were unable to exclude unmeasured potential
confounding factors that may have inﬂuenced our outcomes
because patients were not randomized to diﬀerent treatments.
Although we attempted to control for select variables by using
adjusted models, residual confounding may remain. Finally,
medication usage was measured from ﬁlled prescriptions, and
we cannot conﬁrm that patients adhered to their prescriptions;
however, studies have advocated that pharmacy reﬁll rates and
prescription claims data are a good depiction for actual medication adherence (25). Despite the limitations of this study, we
believe that the data are robust for our large sample within the
US Veteran population and will add to the current literature on
the incidence of colorectal cancer and the use of PDE-5
inhibitors.
Our study evaluated the association of colorectal cancer and
PDE-5 inhibitors among a national cohort of patients with ED
within the VA system. Those who were prescribed PDE-5
inhibitors had a reduced hazard of colorectal cancer compared
with those who were never prescribed PDE-5 inhibitors. For
each additional 100-mg dosage of sildenaﬁl and each additional 10-mg dosage of tadalaﬁl, the hazard of colorectal cancer
was reduced as well. According to our research, clinicians
should monitor and understand the risks and beneﬁts of PDE5 inhibitors with the occurrence of colorectal cancer among
patients with ED. Further research is needed to conﬁrm the
observed association.
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Study Highlights
WHAT IS KNOWN

3 Recent preclinical studies including in vivo, in vitro, and

mouse studies suggest that PDE-5 inhibitor use may reduce
the risk of colorectal cancer.

WHAT IS NEW HERE

3 We use a large national cohort of patients being treated in the
VA and show that PDE-5 inhibitor use is associated with
a lower risk of colorectal cancer.

TRANSLATIONAL IMPACT

3 PDE-5 inhibitors show evidence to support a new drug

development or additional indications for PDE-5 inhibitors.
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